Amgen (AMGN) Prepaid Assets (2009 - 2026)
Amgen (AMGN) recorded quarterly Prepaid Assets of $4.1 billion in Q1 2026, little changed quarter-over-quarter from $4.1 billion in Q4 2025, and up 26.24% on a YoY basis from $3.3 billion in Q1 2025.
Amgen (AMGN) Prepaid Assets (2009 - 2026) Analysis & Trends
Amgen's Prepaid Assets history runs 18 years deep, the most recent figure standing at $4.1 billion for Q1 2026.
- In Q1 2026, Prepaid Assets rose 26.24% year-over-year to $4.1 billion; the TTM figure through Mar 2026 stood at $4.1 billion (up 26.24% YoY), while the FY2025 annual figure was $4.1 billion, up 26.12% from the prior year.
- Prepaid Assets was $4.1 billion for Q1 2026 at Amgen, roughly flat from $4.1 billion in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $4.1 billion in Q4 2025 to a low of $2.3 billion in Q2 2022.
- Historically, Prepaid Assets has averaged $3.0 billion across 5 years, with a median of $2.8 billion in 2024.
- The sharpest annual moves came in 2022 and 2024: Prepaid Assets slipped 6.81% in 2022, then rose 28.06% in 2024.
- A 5-year view of Prepaid Assets shows it stood at $2.4 billion in 2022, then climbed by 8.96% to $2.6 billion in 2023, then advanced by 25.94% to $3.3 billion in 2024, then climbed by 26.12% to $4.1 billion in 2025, then decreased by 0.48% to $4.1 billion in 2026.
- The last three Prepaid Assets figures came in at $4.1 billion (Q1 2026), $4.1 billion (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.11 Bn |
| Dec 31, 2025 | 4.13 Bn |
| Sep 30, 2025 | 3.60 Bn |
| Jun 30, 2025 | 3.42 Bn |
| Mar 31, 2025 | 3.26 Bn |
| Dec 31, 2024 | 3.28 Bn |
| Sep 30, 2024 | 3.08 Bn |
| Jun 30, 2024 | 2.98 Bn |
| Mar 31, 2024 | 2.82 Bn |
| Dec 31, 2023 | 2.60 Bn |
| Sep 30, 2023 | 2.57 Bn |
| Jun 30, 2023 | 2.32 Bn |
| Mar 31, 2023 | 2.40 Bn |
| Dec 31, 2022 | 2.39 Bn |
| Sep 30, 2022 | 2.50 Bn |
| Jun 30, 2022 | 2.26 Bn |
| Mar 31, 2022 | 2.49 Bn |
| Dec 31, 2021 | 2.37 Bn |
| Sep 30, 2021 | 2.54 Bn |
| Jun 30, 2021 | 2.42 Bn |